Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8119775 | Human anti-KIR antibodies Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies hav... | 02/21/2012 |
| 7667007 | αvβ3-specific antibodies The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αvβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Addit... | 02/23/2010 |
| 7560534 | Molecular conjugates comprising human monoclonal antibodies to dendritic cells Molecular conjugates comprising an antigen linked to a human monoclonal antibody that specifically binds to dendritic cells are disclosed. Also disclosed are pharmaceutical compositions comprising the molecular conjugates and therapeutic methods for using the conjug... | 07/14/2009 |
| 7438910 | Therapeutic human anti-IL1-R1 monoclonal antibody Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a ... | 10/21/2008 |
| 7435803 | Anti-CD20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignan... | 10/14/2008 |
| 7435801 | Antibodies and other ligands directed against KIR2DL4 receptor for production of interferon gamma The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC. ... | 10/14/2008 |
| 7435802 | Humanized anti-VLA4 immunoglobulins The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transp... | 10/14/2008 |
| 7425447 | Host cells expressing 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 09/16/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7422745 | Methods of treating cancer with αβ-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide ... | 09/09/2008 |
| 7422744 | Methods of treating cancer with alphavbeta3-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypepti... | 09/09/2008 |
| 7417128 | 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 08/26/2008 |
| 7414123 | Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 08/19/2008 |
| 7410767 | HLA-E binding The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the t... | 08/12/2008 |
| 7371382 | Methods of inhibiting αβ-mediated binding with αβ-specific antibodies The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αVβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Addit... | 05/13/2008 |
| 7361345 | Anti-CD40 antibodies capable of blocking B-cell activation Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the... | 04/22/2008 |
| 7348001 | Tie1-binding ligands Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that inhibit endothelial cell activity. ... | 03/25/2008 |
| 7345153 | Compounds capable of inhibiting HIV-1 infection This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting... | 03/18/2008 |
| 7338660 | Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 03/04/2008 |
| 7321026 | Framework-patched immunoglobulins Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the framewor... | 01/22/2008 |
| 7309489 | Mouse CD40 ligand-specific antibodies and hybridomas There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding r... | 12/18/2007 |
| 7306800 | Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the b... | 12/11/2007 |
| 7297335 | Immunotoxins directed against CD33 related surface antigens The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunot... | 11/20/2007 |
| 7288251 | Antibodies to CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 10/30/2007 |
| 7285269 | Antibodies directed to tumor necrosis factor Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, ... | 10/23/2007 |
| 7262278 | Anti-HLA-DR antibody This invention provides an anti-HLA-DR monoclonal antibody. This invention relates to an antibody binding to HLA-DR or a functional fragment thereof having (a) life-extending effects in nonhuman animals bearing HLA-DR-expressing cancer cells and (b) activity of supp... | 08/28/2007 |
| 7259247 | Anti-human T-cell costimulating polypeptide monoclonal antibodies A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the ... | 08/21/2007 |
| 7223848 | Methods for purifying Fc-containing proteins The present invention provides a process for dissociating Fc-containing molecules from complexes of Protein A/Fc-containing molecules or mixtures containing Fc-containing molecules and Protein A. The association, e.g., by hydrophobic interactions, between the Fc-con... | 05/29/2007 |
| 7211257 | Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF). ... | 05/01/2007 |
| 7193064 | Anti-CD40 monoclonal antibody An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. ... | 03/20/2007 |
| 7192585 | CD80 specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 03/20/2007 |
| 7183108 | Selection and uses of lactic acid bacteria strains modulating non-specific immunity The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fe... | 02/27/2007 |
| 7175847 | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 02/13/2007 |
| 7172759 | Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40. ... | 02/06/2007 |
| 7169389 | Human CD154 binding molecules and treatment methods A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid sequences as defined, for use in the treatment and/or prevention of diseas... | 01/30/2007 |
| 7157086 | Treatment for inflammatory bowel disease with α4-specific antibodies The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel ... | 01/02/2007 |
| 7153508 | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 12/26/2006 |
| 7151164 | Anti-CD20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignan... | 12/19/2006 |
| 7147851 | Humanized immunoglobulin reactive with α4β7 integrin The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework reg... | 12/12/2006 |
| 7132510 | Specific human antibodies for selective cancer therapy The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having... | 11/07/2006 |
